Updates are available Correction dated 2024-07-09

Article History

Received: 12 January 2024

Accepted: 10 April 2024

First Online: 3 June 2024

Change Date: 9 July 2024

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41591-024-03175-4

Competing interests

: F.M. discloses consultancy for AbbVie, Bristol-Myers Squibb, Genmab, Gilead, Novartis and Roche and service as an advisor for AbbVie, Gilead and Roche. S.D. discloses service as an advisor to Bristol-Myers Squibb and Kite/Gilead and research funding from Kite/Gilead. M.L.P. discloses honoraria from Cellectar Biosciences, Ceramedix, Juno Therapeutics, Garuda Therapeutics, Kite, Mustang Bio, Novartis, Pluto Immunotherapeutics, Rheos Medicines, Seres Therapeutics, Smart Immune, Synthekine and ThymoFox and royalties from Juno Therapeutics and Seres Therapeutics. A.M.G.-S. discloses consultancy for AbbVie, ADC Therapeutics America, Celgene, Clinigen, EUSA Pharma, Gilead/Kite, Ideogen, Incyte, Kyowa Kirin, Eli Lilly, Miltenyi Biotec, Novartis, Roche and Takeda; honoraria from Celgene, EUSA Pharma, Gilead/Kite, Janssen, Novartis, Roche and Takeda; travel from Celgene, Gilead/Kite, Janssen and Roche; and service as an advisor for Bristol-Myers Squibb. J.L.R.O. discloses consultancy for Janssen and honoraria from Amgen, Bristol-Myers Squibb and Kite. J. Kuruvilla discloses consultancy for AbbVie, Bristol-Myers Squibb, Gilead, Merck, Roche and Seattle Genetics; honoraria from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Genmab, Gilead, Incyte, Janssen, Merck, Novartis, Pfizer, Roche and Seattle Genetics; service as an advisor for Karyopharm Therapeutics; and research funding from AstraZeneca, Merck and Roche. U.J. discloses honoraria from Bristol-Myers Squibb, Gilead, Janssen, Miltenyi Biotec, Novartis and Roche and research funding from Innovative Medicines Initiative 2 Joint Undertaking. G.C. discloses consultancy for AbbVie, Bristol-Myers Squibb, Emercell, MabQi, MedXCell, Onward Therapeutics and Roche and honoraria from AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Novartis and Roche. K.I. discloses consultancy for AbbVie, AstraZeneca, Eisai, Genmab, Mitsubishi Tanabe Pharma, Ono Pharmaceutical, Otsuka, Nihon Shinyaku, Takeda and Zenyaku; honoraria from AbbVie, AstraZeneca, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Eisai, Genmab, Janssen, Kyowa Kirin, Eli Lilly, Merck Sharp & Dohme, Nihon Kayaku, Novartis, Ono Pharmaceutical, Pfizer, SymBio Pharmaceuticals, Seika Pharma and Takeda; and research funding from AbbVie, Astellas, Amgen, AstraZeneca, BeiGene, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Eisai, Genmab, Incyte, Kyowa Kirin, Loxo Oncology, Merck Sharp & Dohme, Novartis, Otsuka, Pfizer, Regeneron and Yakult. M.D. discloses honoraria from AstraZeneca, BeiGene, Gilead/Kite, Janssen, Eli Lilly, Novartis and Roche; service as an advisor for AbbVie, AstraZeneca, BeiGene, Celgene, Gilead/Kite, Janssen, Eli Lilly/Loxo, Novartis and Roche; and research funding from AbbVie, Bayer, Celgene, Gilead/Kite, Janssen and Roche. B.K. discloses honoraria from Bristol-Myers Squibb Germany and MSD Oncology and research funding from MSD Oncology and Takeda. H. Ghesquieres discloses consultancy for Gilead and Roche and honoraria from AbbVie, Bristol-Myers Squibb, Gilead and Roche. K.A. discloses travel from Bristol-Myers Squibb, Gilead and Novartis. H. Goto discloses honoraria from Bristol-Myers Squibb, Chugai, Novartis, AbbVie, Gilead/Kite, Merck Sharp & Dohme, Daiichi Sankyo, Eisai, Kyowa Kirin and SymBio and research funding from Bristol-Myers Squibb, Kyowa Kirin, Sanofi and SymBio. A.M.B. and S.d.V. declare no competing interests. J.S.A. discloses consultancy for AbbVie, Alimera Sciences, AstraZeneca, BeiGene, bluebird bio, C4 Therapeutics, Caribou Biosciences, Celgene, Century Therapeutics, EMD Serono, Epizyme, Genentech, Genmab, Incyte, Janssen, Karyopharm Therapeutics, Kite/Gilead, Kymera Therapeutics, Eli Lilly, MorphoSys, Mustang Bio, Novartis, Ono Pharmaceutical and Takeda; honoraria from AstraZeneca, Bristol-Myers Squibb, Janssen and Regeneron; and research funding from AI Therapeutics, Bristol-Myers Squibb and Seattle Genetics. P.B. discloses honoraria from Bristol-Myers Squibb Germany and MSD Oncology and research funding from MSD Oncology and Takeda. I.F. discloses consultancy for AbbVie, AstraZeneca, BeiGene, Bristol-Myers Squibb, Gilead, Incyte, Janssen, Novartis, Roche and Seagen and honoraria from Gilead, Incyte, Novartis and Seagen. S.M. discloses honoraria from Celgene, Novartis, Gilead/Kite, Janssen, JAMP Pharma and Pfizer (via institution); service as part of a data safety monitoring board for Immunicum/Mendes and Miltenyi Biotec (via institution); and founding leadership for SWECARNET (via institution) and founder for ScientifyResearch (spouse). A.S. discloses consultancy for Alexion Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Epizyme, Genentech, Genmab, Janssen, Kite, Eli Lilly, MorphoSys, Novartis, Pharmacyclics, Seagen and TG Therapeutics and honoraria from AbbVie, ADC Therapeutics, Alexion Pharmaceuticals, AstraZeneca, BeiGene, Epizyme, Genentech, Genmab, Janssen, Jazz Pharmaceuticals, Kite, MorphoSys, Pharmacyclics, Seagen and TG Therapeutics. M.K. discloses consultancy for AbbVie, Adaptive Biotechnologies, ADC Therapeutics, AstraZeneca, BeiGene, Caribou Biosciences, Celgene, Genentech and Syncopation; service as an advisor for Celgene, Genentech and Seagen; and research funding from Novartis. R.K. discloses consultancy for AstraZeneca, BeiGene, Bristol-Myers Squibb, Calithera Biosciences, Epizyme, Genentech, Janssen, Kite/Gilead, Eli Lilly Oncology, Miltenyi Biotec and MorphoSys; honoraria from AstraZeneca, BeiGene and MorphoSys; and other interests with Bristol-Myers Squibb, Calithera Biosciences, Kite/Gilead and Miltenyi Biotec. A.V. discloses consultancy for AbbVie, Bristol-Myers Squibb, Kite/Gilead and Roche; honoraria from AbbVie, Bristol-Myers Squibb, Kite/Gilead and Roche; and research funding from Bristol-Myers Squibb. T.F., O.F., J.L., M.V., R.N., A.A., J.P. and J. Kumar are employees and equity holders of Bristol-Myers Squibb. L.J.N. discloses consultancy for Interius Biotherapeutics and SIRPant Immunotherapeutics; honoraria from ADC Therapeutics, Bristol-Myers Squibb, Caribou Biosciences, Epizyme, Genentech, Genmab, Gilead, Janssen Oncology, MorphoSys, Novartis, Roche, Takeda and TG Therapeutics; and travel from Genentech/Roche.